- Home
- SPRB vs INAB Comparison
SPRB vs INAB Comparison
Compare SPRB & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRB
- INAB
- Stock Information
- Founded
- SPRB 2014
- INAB 2016
- Country
- SPRB United States
- INAB United States
- Employees
- SPRB N/A
- INAB N/A
- Industry
- SPRB Medicinal Chemicals and Botanical Products
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SPRB Health Care
- INAB Health Care
- Exchange
- SPRB Nasdaq
- INAB Nasdaq
- Market Cap
- SPRB 22.8M
- INAB 23.5M
- IPO Year
- SPRB 2020
- INAB 2021
- Fundamental
- Price
- SPRB $0.52
- INAB $0.36
- Analyst Decision
- SPRB Hold
- INAB Strong Buy
- Analyst Count
- SPRB 7
- INAB 3
- Target Price
- SPRB $2.50
- INAB $7.75
- AVG Volume (30 Days)
- SPRB 400.8K
- INAB 2.7M
- Earning Date
- SPRB 11-11-2024
- INAB 11-12-2024
- Dividend Yield
- SPRB N/A
- INAB N/A
- EPS Growth
- SPRB N/A
- INAB N/A
- EPS
- SPRB N/A
- INAB N/A
- Revenue
- SPRB $7,101,000.00
- INAB N/A
- Revenue This Year
- SPRB N/A
- INAB N/A
- Revenue Next Year
- SPRB N/A
- INAB N/A
- P/E Ratio
- SPRB N/A
- INAB N/A
- Revenue Growth
- SPRB N/A
- INAB N/A
- 52 Week Low
- SPRB $0.41
- INAB $0.22
- 52 Week High
- SPRB $5.95
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- SPRB 47.26
- INAB 50.42
- Support Level
- SPRB $0.51
- INAB $0.31
- Resistance Level
- SPRB $0.56
- INAB $0.37
- Average True Range (ATR)
- SPRB 0.03
- INAB 0.04
- MACD
- SPRB -0.01
- INAB 0.01
- Stochastic Oscillator
- SPRB 16.61
- INAB 38.51
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.